We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+45.08%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$930M
AUM Growth
+$84.2M
Cap. Flow
+$7.86M
Cap. Flow %
0.85%
Top 10 Hldgs %
65.22%
Holding
58
New
12
Increased
4
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$70.3M
2
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22M
3
CHRS icon
Coherus Oncology
CHRS
+$21.9M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$20M
5
TGTX icon
TG Therapeutics
TGTX
+$16.7M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$64.2M
2
DYAX
DYAX CORPORATION
DYAX
+$35.8M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$34.8M
4
DVAX
Dynavax Technologies
DVAX
+$17.4M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 73.37%
2 Miscellaneous 26.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
51
Puma Biotechnology
PBYI
$477M
$587K 0.06%
3,100
– –
CDXS icon
52
Codexis
CDXS
$153M
– –
-504,279
Closed -$1.18M
DVAX
53
DELISTED
Dynavax Technologies
DVAX
– –
-1,217,900
Closed -$17.4M
ENTA icon
54
Enanta Pharmaceuticals
ENTA
$358M
– –
-250,000
Closed -$9.89M
VRTX icon
55
Vertex Pharmaceuticals
VRTX
$130B
– –
-9,300
Closed -$1.04M
VIRX
56
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-23,187
Closed -$34.8M
ALIM
57
DELISTED
Alimera Sciences
ALIM
– –
-16,248
Closed -$1.32M
AVNR
58
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-5,386,700
Closed -$64.2M
1 2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, RA Capital Management held 58 positions worth $930M, up 10% from $846M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management's Q4 2014 filing shows 12 new, 4 increased, 10 reduced and 7 closed positions. Its largest new stake was Regulus Therapeutics: 39,524 shares worth $76.1M. The largest sale was AVANIR PHARMACEUTICALS, INC CL A, an estimated $64.2M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 54% a quarter earlier, followed by Miscellaneous.

  • RA Capital Management's largest Q4 2014 buy was Regulus Therapeutics: 39,524 shares worth $76.1M.
  • RA Capital Management added most to TG Therapeutics in Q4 2014, an estimated $16.7M increase.
  • RA Capital Management's biggest Q4 2014 reduction was DYAX CORPORATION, cutting an estimated $35.8M.
  • RA Capital Management fully exited AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, selling an estimated $64.2M.
  • RA Capital Management's ten largest holdings make up 65% of its $930M portfolio in Q4 2014.
  • RA Capital Management opened 12 new positions and closed 7 in Q4 2014.
  • RA Capital Management's portfolio value rose 10% quarter-over-quarter to $930M.

Based on RA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.